Published in PLoS One on October 14, 2013
The dual role of LSD1 and HDAC3 in STAT5-dependent transcription is determined by protein interactions, binding affinities, motifs and genomic positions. Nucleic Acids Res (2016) 0.75
TACI expression and signaling in chronic lymphocytic leukemia. J Immunol Res (2015) 0.75
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol (1997) 12.11
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
STATs: signal transducers and activators of transcription. Cell (1996) 6.10
Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell (1985) 6.06
Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell (1998) 5.92
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res (2002) 5.84
MicroRNA-mediated conversion of human fibroblasts to neurons. Nature (2011) 5.59
Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev (1997) 5.57
Transitions in histone acetylation reveal boundaries of three separately regulated neighboring loci. EMBO J (2001) 4.28
Efficient biotinylation and single-step purification of tagged transcription factors in mammalian cells and transgenic mice. Proc Natl Acad Sci U S A (2003) 4.28
Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A (1997) 4.11
CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood (1997) 3.08
Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression. Nat Immunol (2008) 2.31
Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J (1999) 2.10
Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res (2009) 2.03
Regulation of muscle development by DPF3, a novel histone acetylation and methylation reader of the BAF chromatin remodeling complex. Genes Dev (2008) 1.96
Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med (1992) 1.86
Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med (2005) 1.72
Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res (2009) 1.72
Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol (2004) 1.64
Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem (1999) 1.64
BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. Leuk Res (2009) 1.64
Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev (1999) 1.54
STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood (1997) 1.53
Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification. J Biol Chem (2004) 1.53
Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res (2004) 1.47
Extracellular matrix-regulated gene expression requires cooperation of SWI/SNF and transcription factors. J Biol Chem (2007) 1.46
Dynamic, sex-differential STAT5 and BCL6 binding to sex-biased, growth hormone-regulated genes in adult mouse liver. Mol Cell Biol (2011) 1.36
Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res (2005) 1.26
Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med (1993) 1.20
STAT5 in B cell development and leukemia. Curr Opin Immunol (2010) 1.19
In vivo identification of novel STAT5 target genes. Nucleic Acids Res (2008) 1.19
Sequential activation of genetic programs in mouse mammary epithelium during pregnancy depends on STAT5A/B concentration. Nucleic Acids Res (2012) 1.16
Comprehensive meta-analysis of Signal Transducers and Activators of Transcription (STAT) genomic binding patterns discerns cell-specific cis-regulatory modules. BMC Genomics (2013) 1.12
The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood (2007) 1.12
APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica (2007) 1.11
Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood (2007) 1.08
Genome-wide analyses reveal the extent of opportunistic STAT5 binding that does not yield transcriptional activation of neighboring genes. Nucleic Acids Res (2012) 1.04
Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changes. Genes Chromosomes Cancer (2007) 1.03
Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. Int J Cancer (1986) 1.02
Ubiquitous expression of the rtTA2S-M2 inducible system in transgenic mice driven by the human hnRNPA2B1/CBX3 CpG island. BMC Dev Biol (2007) 1.00
Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood (1996) 1.00
Three distinct patterns of histone H3Y41 phosphorylation mark active genes. Cell Rep (2012) 0.95
Establishment of a karyotypically normal B-chronic lymphocytic leukemia cell line; evidence of leukemic origin by immunoglobulin gene rearrangement. Leuk Res (1990) 0.92
Comparison of HIV- and EIAV-based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells. Mol Ther (2005) 0.91
Proteomic analysis of progressive factors in uterine cervical cancer. Proteomics (2005) 0.86
Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leuk Res (2006) 0.86
An embryonic-specific repressor element located 3' to the Agamma-globin gene influences transcription of the human beta-globin locus in transgenic mice. Exp Hematol (2004) 0.83
Interleukin-7 induces apoptosis of 697 pre-B cells expressing dominant-negative forms of STAT5: evidence for caspase-dependent and -independent mechanisms. Oncogene (2004) 0.82
Differential role of Stat5 isoforms in effecting hematopoietic recovery induced by Mpl-ligand in lethally myelosuppressed mice. Exp Hematol (2003) 0.81
Non-malignant leukocytes delay spontaneous B-CLL cell apoptosis. Leukemia (2001) 0.81
Interferon-alpha-mediated prevention of in vitro apoptosis of chronic lymphocytic leukemia B cells: role of bcl-2 and c-myc. Clin Immunol Immunopathol (1994) 0.79
Protein complexes and target genes identification by in vivo biotinylation: the STAT5 paradigm. Sci Signal (2012) 0.77
Production of colony-stimulating activity by normal and neoplastic human B lymphocytes. Blood (1987) 0.76
Efficient biotinylation and single-step purification of tagged transcription factors in mammalian cells and transgenic mice. Proc Natl Acad Sci U S A (2003) 4.28
SLC40A1-R178G mutation and ferroportin disease. J Hepatol (2011) 1.97
Foxp3 expression in human cancer cells. J Transl Med (2008) 1.94
BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci (2006) 1.59
The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol (2010) 1.50
Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist (2008) 1.47
Activation of bone morphogenetic protein/Smad signaling in bronchial epithelial cells during airway inflammation. Am J Respir Cell Mol Biol (2002) 1.45
Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol (2003) 1.37
Regulation of the autophagic machinery in human neutrophils. Eur J Immunol (2010) 1.26
The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn (2012) 1.24
A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res (2007) 1.22
Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res (2003) 1.20
The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. Adv Hematol (2011) 1.20
Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate (2003) 1.19
The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res (2003) 1.15
Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. J Proteome Res (2009) 1.13
Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res (2009) 1.12
A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem (2006) 1.12
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol (2004) 1.11
Specific nuclear envelope transmembrane proteins can promote the location of chromosomes to and from the nuclear periphery. Genome Biol (2013) 1.11
Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. Mol Cancer (2014) 1.05
Cell-specific and lamin-dependent targeting of novel transmembrane proteins in the nuclear envelope. Cell Mol Life Sci (2010) 1.02
B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol (2007) 1.02
Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res (2007) 1.01
The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. Am J Pathol (2013) 1.00
Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res (2003) 0.97
Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem (2010) 0.96
Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem (2012) 0.96
Colon cancer and protein arginine methyltransferase 1 gene expression. Anticancer Res (2009) 0.96
Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. Clin Biochem (2002) 0.94
Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin Biochem (2003) 0.94
Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Lett (2004) 0.94
Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. Clin Chem (2002) 0.94
Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res (2003) 0.93
Polyadenylate polymerase modulations in human epithelioid cervix and breast cancer cell lines, treated with etoposide or cordycepin, follow cell cycle rather than apoptosis induction. Biol Chem (2005) 0.92
Liver FOXP3 and PD1/PDL1 Expression is Down-Regulated in Chronic HBV Hepatitis on Maintained Remission Related to the Degree of Inflammation. Front Immunol (2013) 0.92
Clinical evaluation of PRMT1 gene expression in breast cancer. Tumour Biol (2011) 0.92
The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner. Cancer Chemother Pharmacol (2007) 0.92
Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thromb Haemost (2009) 0.92
Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin Cancer Res (2006) 0.92
Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb Haemost (2004) 0.91
Molecular profile of the BCL2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs. Connect Tissue Res (2008) 0.91
Human tissue kallikreins: from gene structure to function and clinical applications. Adv Clin Chem (2005) 0.91
Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res (2005) 0.91
Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. Lab Invest (2011) 0.91
Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. Tumour Biol (2012) 0.91
Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol Chem (2012) 0.90
Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol (2003) 0.90
Toll-like receptor 4 gene (TLR4), but not TLR2, polymorphisms modify the risk of tonsillar disease due to Streptococcus pyogenes and Haemophilus influenzae. Clin Vaccine Immunol (2010) 0.89
p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. In Vivo (2005) 0.89
FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia. BMC Blood Disord (2009) 0.89
Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett (2006) 0.89
Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. Tumour Biol (2004) 0.89
Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. Clin Biochem (2004) 0.89
Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biol Chem (2006) 0.88
Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients. Clin Chem Lab Med (2014) 0.87
Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene BCL2L12 in colon cancer. Biol Chem (2008) 0.87
Low expression of interferon regulatory factor-1 and identification of novel exons skipping in patients with chronic myeloid leukaemia. Br J Haematol (2002) 0.87
Comparative study of balloon and metal olive dilators for endoscopic management of benign anastomotic rectal strictures: clinical and cost-effectiveness outcomes. Surg Endosc (2010) 0.87
Quantitative expression analysis and prognostic significance of the BCL2-associated X gene in nasopharyngeal carcinoma: a retrospective cohort study. BMC Cancer (2013) 0.87
Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor. Tumour Biol (2010) 0.87
Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. Ann N Y Acad Sci (2006) 0.86
The effect of the polyadenylation inhibitor cordycepin on human Molt-4 and Daudi leukaemia and lymphoma cell lines. Cancer Chemother Pharmacol (2007) 0.86
Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Int J Cancer (2003) 0.86
Evolution of the plasma and tissue kallikreins, and their alternative splicing isoforms. PLoS One (2013) 0.86
Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol (2010) 0.86
BCL2L12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. Mol Med (2010) 0.86
Association between kallikrein-related peptidases (KLKs) and macroscopic indicators of semen analysis: their relation to sperm motility. Biol Chem (2009) 0.85
Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). Cancer Sci (2008) 0.85
Molecular response of HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, including the new member BCL2L12. Ann N Y Acad Sci (2009) 0.85
Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer. Clin Biochem (2013) 0.85
Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer. Biol Chem (2004) 0.85
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. Clin Cancer Res (2007) 0.85
Molecular analysis and prognostic impact of the novel apoptotic gene BCL2L12 in gastric cancer. Biochem Biophys Res Commun (2009) 0.85
Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer. Clin Biochem (2008) 0.84
Successful treatment of extramedullary plasmacytoma of the cavernous sinus using a combination of intermediate dose of thalidomide and dexamethasone. Acta Haematol (2006) 0.84
The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res Treat (2003) 0.84
Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. Urology (2002) 0.84
Expression analysis and study of KLK4 in benign and malignant breast tumours. Thromb Haemost (2009) 0.84
Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. Ann N Y Acad Sci (2003) 0.84
Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin Chem (2002) 0.84
Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clin Chem Lab Med (2012) 0.84
Persistent fetal gamma-globin expression in adult transgenic mice following deletion of two silencer elements located 3' to the human Agamma-globin gene. Mol Med (2009) 0.84
Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis. Hum Pathol (2011) 0.84
Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thromb Haemost (2003) 0.84
Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumour Biol (2011) 0.83
Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. Pathol Res Pract (2012) 0.83
Kallikreins as markers of disseminated tumour cells in ovarian cancer-- a pilot study. Tumour Biol (2006) 0.83
Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. Clin Chem (2006) 0.83
Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate (2002) 0.83
Methylation status of RASSF1A in patients with chronic myeloid leukemia. Leuk Res (2009) 0.83
Structure and biological properties of the copper(II) complex with the quinolone antibacterial drug N-propyl-norfloxacin and 2,2'-bipyridine. J Inorg Biochem (2006) 0.83
Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma. Tumour Biol (2014) 0.83
Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors. Tumour Biol (2012) 0.83
Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis. Int Immunol (2003) 0.83
Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci (2007) 0.83
The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res (2003) 0.82
Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J Urol (2003) 0.82
Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series. Onkologie (2005) 0.82
Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions. Clin Proteomics (2011) 0.82